FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2132173613> ?p ?o ?g. }

• W2132173613 endingPage "2865" @default.
• W2132173613 startingPage "2860" @default.
• W2132173613 abstract "HomeCirculationVol. 116, No. 24Carcinoid Heart Disease Free AccessReview ArticlePDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessReview ArticlePDF/EPUBCarcinoid Heart Disease Sanjeev Bhattacharyya, Joseph Davar, Gilles Dreyfus and Martyn E. Caplin Sanjeev BhattacharyyaSanjeev Bhattacharyya From the Carcinoid Heart Disease Clinic, Department of Cardiology (S.B., J.D.), and Neuroendocrine Tumour Unit (M.E.C.), Royal Free Hospital, and Department of Cardiothoracic Surgery, Royal Brompton and Harefield NHS Trust (G.D.), London, UK. Search for more papers by this author , Joseph DavarJoseph Davar From the Carcinoid Heart Disease Clinic, Department of Cardiology (S.B., J.D.), and Neuroendocrine Tumour Unit (M.E.C.), Royal Free Hospital, and Department of Cardiothoracic Surgery, Royal Brompton and Harefield NHS Trust (G.D.), London, UK. Search for more papers by this author , Gilles DreyfusGilles Dreyfus From the Carcinoid Heart Disease Clinic, Department of Cardiology (S.B., J.D.), and Neuroendocrine Tumour Unit (M.E.C.), Royal Free Hospital, and Department of Cardiothoracic Surgery, Royal Brompton and Harefield NHS Trust (G.D.), London, UK. Search for more papers by this author and Martyn E. CaplinMartyn E. Caplin From the Carcinoid Heart Disease Clinic, Department of Cardiology (S.B., J.D.), and Neuroendocrine Tumour Unit (M.E.C.), Royal Free Hospital, and Department of Cardiothoracic Surgery, Royal Brompton and Harefield NHS Trust (G.D.), London, UK. Search for more papers by this author Originally published11 Dec 2007https://doi.org/10.1161/CIRCULATIONAHA.107.701367Circulation. 2007;116:2860–2865Carcinoid tumors are relatively rare neuroendocrine malignancies most commonly originating from enterochromaffin cells in the gastrointestinal tract. The incidence is ≈1 in 100 000 of the general population.1 They usually grow slowly over years, commonly causing no symptoms at all until they become large or have metastasized. Carcinoid tumors of midgut origin may secrete large amounts of vasoactive substances, including 5-hydroxytryptamine (5-HT), tachykinins, and prostaglandins. These are largely inactivated by the liver. Carcinoid syndrome occurs when tumor cells metastasize to the liver as the vasoactive substances produced are able to reach the systemic circulation via the hepatic vein. Clinically, this is characterized by flushing, diarrhea, and bronchospasm.Over the past decade, several new therapies for carcinoid tumors have emerged to reduce symptoms and cause tumor regression. Most notably, the development of somatostatin analogs, which inhibit the release of various biogenic amines and peptides, including serotonin, has resulted in a marked improvement in symptoms.2 These may also have contributed to increased survival, although this has not been proved.2,3 Rarely, surgical resection is curative for nonmetastatic disease. Otherwise, reduction of symptoms, improvement in quality of life, and improvement in survival by inhibition of tumor hormones or reduction of tumor load are the main goals. Metastatic disease of the liver may be debulked either surgically or by hepatic artery embolization in selected patients. Interferon therapy and targeted radionuclide therapy may stabilize or reduce the tumor. Chemotherapy is rarely an option except for pancreatic, bronchial, and high-grade neuroendocrine tumors.Carcinoid heart disease (CHD) was first reported in 1954.4 Several series have reported CHD in up to 70% of cases of carcinoid syndrome.5,6 Development is thought to relate to the vasoactive substances secreted by the metastatic tumor cells in the liver, reaching the right heart. This is associated with deposition of fibrous tissue on the endocardial surfaces of the heart. More recent reports have suggested that this number has reduced, perhaps as a result of the introduction of somatostatin analogs and other antitumor therapies designed to reduce the tumor load and the production of tumor secretory products.7 Exceptionally, CHD may present in carcinoid tumors without liver metastases or in primary ovarian carcinoid tumors in which 5-HT is thought to reach the systemic circulation directly, bypassing portal circulation and the liver.8,9PresentationsUp to 20% of patients with carcinoid syndrome present with CHD at diagnosis. CHD is remarkably well tolerated initially. Patients may be in functional New York Heart Association class I despite severe right-sided valve lesions. Eventually, the signs and symptoms of right heart failure, including shortness of breath on exertion, ankle edema, and fatigue, develop as CHD progresses. Case reports have demonstrated presentations resulting from pericardial effusions, restrictive cardiomyopathy,10 constrictive pericarditis,11 and patent foramen ovale presenting with cyanosis and hypoxia secondary to a combination of right heart disease and interatrial shunts.12Clinical ExaminationInitially, clinical examination reveals prominent CV waves of tricuspid regurgitation; a right ventricular heave can be palpated; and auscultation reveals the pansystolic murmur of tricuspid regurgitation, early diastolic murmur of pulmonary regurgitation, and systolic murmur of pulmonary stenosis at the left sternal edge. Murmurs may be difficult to detect because velocities in the right heart are low. Peripheral edema, ascites, and pulsatile hepatomegaly develop as the disease progresses.Biochemical Markers and Pathogenesis of CHDThe pathogenesis of CHD and the development of carcinoid plaques remain incompletely understood, although a growing body of evidence points toward serotonin (5-HT) playing a key role.Evidence for 5-HT–induced valvulopathy has arisen from a variety of sources. The appetite suppressants fenfluramine and phentermine have been withdrawn from the market because of the development of valve pathology with changes similar to those seen in carcinoid patients.13 These drugs display a serotonergic action on human tissue.14Carcinoid heart valves demonstrate accumulation of tissue growth factor-β latency–associated peptide and latent binding protein.15 5-HT has been shown to increase synthesis and upregulate tissue growth factor-β, as well as stimulating collagen synthesis by heart valve interstitial cells.16 These findings may contribute to the pathophysiology of carcinoid heart valve involvement because 5-HT receptors are present in human heart valves.In animal models, both long-term 5-HT administration and the deficiency of 5-hydroxyindoleacetic acid (5-HIAA) transporter gene can induce morphological and echocardiographic changes consistent with cardiac fibrosis and valvulopathy similar to those seen in human CHD.17,185-HT is metabolized to urinary 5-HIAA by monoamine oxidases in the liver. Mean 5-HIAA level has a high sensitivity (100%) but a very low specificity for the development of CHD. Therefore, it has been postulated that although 5-HT is important, other factors combined with serotonin must be required for the development of CHD.19 The tachykinins neuropeptide K and substance P have been shown to be elevated in CHD and may be an important part of the pathogenesis of CHD.6 Peak 5-HIAA is a significant predictor of the progression of CHD.20N-terminal brain natriuretic peptides are released by the atria and ventricles of the heart in response to wall stress.21 Brain natriuretic peptide is released in a variety of valvular lesions and ventricular dysfunction. Significantly greater median levels of N-terminal brain natriuretic peptides are found in patients with CHD than in those without CHD. A high sensitivity may allow accurate differentiation between those with and without CHD and its use as a possible screening test for CHD.7Morphological and Histological Features of CHDThe carcinoid plaque, composed of smooth muscle cells, myofibroblasts, and elastic tissue, forms a white fibrous layer lining the endocardial surface of cardiac valves superficial to normal valve tissue. Native, underlying valve morphology is unharmed.22 Plaques develop on the endocardium of the right ventricle and atrium, the valve leaflets, and the subvalvular apparatus, including chordae and papillary muscle. Deposition of plaques has been found in the vena cava, pulmonary artery, coronary sinus, and coronary arteries.23 The tricuspid valve plaques have a preponderance to develop on the ventricular side of the leaflets, causing adherence to mural endocardium and creating a substrate for regurgitation of blood volume. Fibrous tissue at the valve annulus causes constriction at the ring, resulting in a degree of valvular stenosis. For the pulmonary valve, the predominant lesion is stenosis because plaques develop at the pulmonic root, causing constriction of the root and diminishing an already small orifice.24InvestigationsECG and Chest X-RayThe ECG and chest x-ray may provide clues to the diagnosis of CHD. The cardiothoracic ratio may be enlarged. The ECG in patients with CHD has a higher frequency of low-voltage QRS complexes in CHD patients than those without; however, they are not sensitive.5,24Cardiac Imaging in CHDEchocardiographyThe echocardiographic features of CHD are well described.5,25 Appearances are pathognomic in the absence of exposure to the appetite suppressants fenfluramine and phentermine, ergot-derived dopamine agonists, and ergot alkaloid agents such as methysergide and ergotamine.13,26Multiple views of each valve should be obtained for optimal evaluation of right-sided heart valves. The tricuspid valve is visualized in the parasternal long-axis view of the right ventricular inflow tract, parasternal short-axis view, apical 4-chamber view, and subcostal long-axis view. The pulmonary valve is visualized in the parasternal long-axis view of the right ventricular outflow tract, parasternal short-axis view, and subcostal short-axis view.27Classically, both tricuspid and pulmonary valve leaflets and their corresponding subvalvular apparatus are thickened. Excursion of the leaflets is reduced. Eventually, valve leaflets become retracted, fixed, and noncoapting, leading to the valve remaining in a semiopen position. Functionally, a combination of valvular regurgitation and stenosis occurs (Figures 1 and 2). A “dagger-shaped” continuous-wave Doppler profile, resulting from severe tricuspid regurgitation that causes early peak pressure and rapid decline and representing equalization of right atrial and ventricular pressures, is seen in severe disease. The tricuspid valve, with or without pulmonary valve involvement, is involved in most cases of CHD. Indeed, it is the combination of these that creates the most hemodynamic disturbance. Pulmonary stenosis is thought to worsen the severity of tricuspid regurgitation; conversely, the severity of pulmonary stenosis may be underestimated because of low cardiac output and severe tricuspid regurgitation. Download figureDownload PowerPointFigure 1. Carcinoid involvement of pulmonary valve (PV). A, Right ventricular outflow tract. Thickened, fixed, and retracted pulmonary valve leaflets that do not coapt. B, Continuous-wave Doppler of pulmonary valve shows pulmonary regurgitation (PR) with short deceleration time and pulmonary stenosis (PS). C, Parasternal short-axis view of pulmonary valve. Shortened and retracted valve leaflets. D, Color Doppler in diastole demonstrates turbulent pulmonary regurgitant flow.Download figureDownload PowerPointFigure 2. Carcinoid involvement of tricuspid valve (TV). A, Right ventricular inflow view. Fixed, retracted, and thickening of tricuspid valve leaflets and associated chordae. B, Continuous-wave Doppler showing dagger-shaped profile of tricuspid regurgitation (TR). C, Apical 4-chamber view showing dilated right ventricle with tricuspid valve leaflets failing to coapt resulting in constant semiopen position. D, Color Doppler demonstrating severe tricuspid regurgitation into a dilated right atrium.The right atrium and ventricle are typically enlarged. As the ventricle becomes volume overloaded, paradoxical motion of the interventricular septum occurs. Right ventricular function seemingly remains intact until quite late in the disease course. The increasing elevation in right ventricular pressure and increasing size of the right atrium may lead to reopening of patent foramen ovale in severe CHD.28Left-sided lesions occur in up to 15% of all cases.5,29 Involvement is characterized by diffuse thickening of valve leaflets and is usually less severe than right-sided valvular lesions (Figure 3). Serotonin is thought to be inactivated as it passes through lung parenchyma.30 Involvement of left-sided valves is thought to be due to the presence of a patent foramen ovale with a right-to-left shunt, bronchial carcinoid, or high levels of circulating vasoactive substances. Small pericardial effusions are present in up to 10% of cases. Myocardial metastases are rare.31 When transthoracic echocardiography cannot adequately visualize structures, transesophageal echocardiography should be undertaken.32Download figureDownload PowerPointFigure 3. Left-sided CHD. A, Parasternal long-axis view. Carcinoid involvement of aortic valve (AV). Diffuse and grossly thickened noncoronary cusp (NCC) of aortic valve. Normal right coronary cusp. B, Parasternal long-axis view. Carcinoid involvement of mitral valve (MV). Diffusely thickened mitral valve leaflets and associated chordae.Cardiac Magnetic Resonance Imaging/64-Slice Computed TomographyCardiac magnetic resonance imaging has been shown to provide clear anatomic and functional information on both the pulmonary and tricuspid valve in CHD. This can be of use, particularly in evaluating the pulmonary valve when it is difficult to visualize by echocardiography and when limited ultrasound acoustic windows provide sparse echocardiographic data or in providing accurate data of right ventricular function.33,34 Recently, 64-slice coronary angiography has demonstrated similar anatomic information.34ManagementWithout intervention, CHD patients may develop progressively worsening symptomatic right heart failure. Life expectancy is significantly reduced. The Mayo Clinic showed a mean life expectancy of 1.6 years for those with cardiac disease compared with 4.6 years for those without cardiac disease in patients with metastatic midgut carcinoid tumors.5 Recent improvements in medical and surgical therapy over the past decade may have improved the prognosis.MedicalTreatment of carcinoid disease rarely achieves cure. However, with modern antitumor therapy, its progression can be substantially slowed. Many patients survive for many years after resection of a primary carcinoid tumor or palliative treatment of metastatic disease. Therefore, cardiac intervention should be considered in CHD to offer symptomatic palliation.Medical management consists of relieving symptoms of right heart failure with a combination of loop and thiazide diuretic therapy. The use of digoxin may play a role, but no convincing data for the right ventricle are available. Intuitively, optimizing somatostatin analog therapy should reduce circulating vasoactive substances and carcinoid syndrome and therefore may stabilize CHD.In patients not suitable for cardiac valve surgery, the use of balloon valvuloplasty has been reported.35–37 Identification of suitable patients, with predominantly stenotic valvular lesions, will be problematic in that most patients with CHD also have significant valvular regurgitation. Success of the procedure has been very limited. Although a couple reports have shown some functional and hemodynamic benefit,36,37 others have noted either a lack of symptomatic benefit or a rapid relapse of symptoms and valvular stenosis when initial benefit did occur.35SurgicalCardiac surgery offers definitive therapy for symptoms. Marked symptomatic improvement, of >1 New York Heart Association class, occurs after valve replacement.29,38 There also may be survival benefit with cardiac surgery, although this is difficult to prove, given the other morbidities of this patient group. Median survival of 6 years with the greatest at 11 years after cardiac valve replacement compares very favorably with medically treated patients. Several series report high perioperative mortality, although the operative risk has declined from >20% in the 1980s to <10% more recently.39 The main perioperative complications are bleeding and right ventricular failure. Despite some patients having relatively mild pulmonary valve disease, pulmonary valve replacement in addition to tricuspid valve replacement has been shown to reduce right ventricular size after surgery compared with patients with isolated tricuspid valve replacement. Right ventricular dysfunction may not recover postoperatively.40 The optimal timing of surgery in relation to the severity of valve dysfunction and symptoms has not been identified. However, on the basis of these data, cardiac surgery at the onset of either symptoms or right ventricular dysfunction with pulmonary valve replacement in addition to replacement of the tricuspid valve may be considered prudent.More controversial is the choice of valve prosthesis. No large series have compared the choice of valve prosthesis. Initial reports favored the use of mechanical prosthesis on the basis of the assumption of damage to a bioprosthetic valve with vasoactive substances. There have been several case reports of bioprosthetic valve degeneration.41–43 Carcinoid plaques have caused pulmonary valve allograft failure as early as 3 months after implantation42 and tricuspid biological graft dysfunction after as little as 4 years.43 However, the advent of somatostatin analogs and other antitumor therapies may theoretically protect the valve from deposition of further carcinoid plaques. Tissue valves have the advantage of not requiring anticoagulation and consequently lower the risk of bleeding in patients with hepatic dysfunction, reduce the risk of valve thrombosis (mechanical valve thrombosis is 4% per year44), and allow further procedures such as hepatic dearterialization to proceed at a later date. Therefore, choice of prosthesis should be tailored to individual patient risk of bleeding, life expectancy, and future interventions.There have been several reports of patients presenting with dyspnea, hypoxia, and cyanosis. Interatrial shunts via patent foramen ovale associated with valvular disease were described. Surgical closure of patent foramen ovale and percutaneous transcatheter closure devices in patients at high surgical risk have produced dramatic relief of symptoms.45,46 Elevated right atrial pressure secondary to valvular disease may have contributed to stretching of the foramen ovale and development of a right-to-left shunt.Perioperative Anesthetic ManagementCarcinoid crises characterized by hypotension, bronchospasm, and flushing can be precipitated by surgery and by drugs that release catecholamine and histamines. During the perioperative period, it can be difficult to differentiate between carcinoid crisis and hypotension secondary to myocardial dysfunction. Perioperative octreotide, aimed at reducing serotonin release, is the most efficacious treatment for preventing crises during surgery and is the mainstay treatment of carcinoid crisis.47,48 Intravenous octreotide (50 to 100 μg/h) should be started at least 2 hours before surgery. The infusion should continue for 48 hours after surgery. Patients may then require subcutaneous octreotide, depending on previous somatostatin analog requirements and current control of carcinoid syndrome. Avoiding or minimizing the use of drugs known to precipitate mediator release such as opioids, the neuromuscular relaxant atracurium, and catecholamine producers like dopamine and epinephrine may reduce the risk of carcinoid crisis.48,49ConclusionsAlthough carcinoid tumors are rare malignancies, cardiac involvement is relatively common. Despite severe disease, patients may possess relatively few signs or symptoms in the early stages. Echocardiography is the investigation of choice, revealing a unique valvular appearance. Gradual decline in right ventricular function and increasing severity of valvular disease lead to right heart failure and a poor outlook if treated medically. In view of the increasing longevity of patients with carcinoid tumors as a result of better control of carcinoid symptoms and treatment of metastatic disease, patients should be considered for surgical therapy to relieve cardiac symptoms. A multidisciplinary team experienced in dealing with these complex patients is required to provide informed decisions on optimal patient management.DisclosuresNone.FootnotesCorrespondence to Dr Joseph Davar, Carcinoid Heart Disease Clinic, Department of Cardiology, Royal Free Hospital, Pond St, London, NW3 2QG, UK. E-mail [email protected] References 1 Modlin IM, Sandor A. An analysis of 8305 cases of carcinoid tumors. Cancer. 1997; 79: 813–829.MedlineGoogle Scholar2 Caplin M, Buscombe J, Hilson A, Jones AL, Watkinson AF, Burroughs AK. Carcinoid tumour. Lancet. 1998; 352: 799–805.CrossrefMedlineGoogle Scholar3 Quaedvlieg P, Visser O, Lamers C, Janssen-Heijen M, Taal B. Epidemiology and survival in patients with carcinoid disease in the Netherlands. Ann Oncol. 2001; 12: 1295–1300.CrossrefMedlineGoogle Scholar4 Thorson A, Biorck G, Bjorkman G, Waldenstrom J. Malignant carcinoid of the small intestine with metastases to the liver, valvular disease of the right side of the heart (pulmonary stenosis and tricuspid regurgitation without septal defects), peripheral vasomotor symptoms, bronchoconstriction, and an unusual type of cyanosis: a clinical and pathologic syndrome. Am Heart J. 1954; 47: 795–817.CrossrefMedlineGoogle Scholar5 Pellika PA, Tajik AJ, Khandheria BK, Seward JB, Callahan JA, Pitot HC, Kvols LK. Carcinoid heart disease: clinical and echocardiographic spectrum in 74 patients. Circulation. 1993; 87: 1188–1196.CrossrefMedlineGoogle Scholar6 Lundin L, Norheim I, Landelius J, Oberg K, Theodorsson-Norheim E. Relationship of circulating vasoactive substances to ultrasound detectable cardiac abnormalities. Circulation. 1988; 77: 264–269.CrossrefMedlineGoogle Scholar7 Zuetenhorst J, Korse C, Bonfrer J, Bakker RH, Taal B. Role of natriuretic peptides in the diagnosis and treatment of patients with carcinoid heart disease. Br J Cancer. 2004; 90: 2073–2079.CrossrefMedlineGoogle Scholar8 Chaowalit N, Connolly HM, Schaff HV, Webb MJ, Pellikka PA. Carcinoid heart disease associated with primary ovarian carcinoid tumour. Am J Cardiol. 2004; 93: 1314–1315.CrossrefMedlineGoogle Scholar9 Bernheim AM, Connolly HM, Pellikka PA. Carcinoid heart disease in patients without hepatic metastases. Am J Cardiol. 2007; 99: 292–294.CrossrefMedlineGoogle Scholar10 McGuire MR, Pugh DM, Dunn MI. Carcinoid heart disease: restrictive cardiomyopathy as a late complication. J Kans Med Soc. 1978; 79: 661–662.MedlineGoogle Scholar11 Rich LL, Lisa CP, Nasser WK. Carcinoid pericarditis. Am J Med. 1973; 54: 522–527.CrossrefMedlineGoogle Scholar12 Blick DR, Zoghbi WA, Lawrie GM, Verani MS. Carcinoid heart disease presenting as right to left shunt and congestive heart failure: successful surgical treatment. Am Heart J. 1988; 115: 201–203.CrossrefMedlineGoogle Scholar13 Connolly H, Crary J, McGoon M, Hensrud DD, Edwards BS, Edwards WD, Schaff HV. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med. 1997; 337: 581–588.CrossrefMedlineGoogle Scholar14 Jagroop I, Mikhailidis D. An investigation of the serotonergic effects of fenfluramine, dexfenfluramine and dexnorfenfluramine using platelets as neuronal models. Platelets. 2000; 11: 161–165.CrossrefMedlineGoogle Scholar15 Waltenberger J, Lundin L, Oberg K, Willander E, Miyazono K, Heldin CH, Funa K. Involvement of transforming growth factor in the formation of fibrotic lesions in carcinoid heart disease. Am J Pathol. 1993; 142: 71–78.MedlineGoogle Scholar16 Jian B, Xu J, Connolly J, Savani RC, Narula N, Liang B, Levy RJ. Serotonin mechanisms in heart valve disease, I: serotonin-induced up-regulation of transforming growth factor β1 via G-protein signal transduction in aortic valve interstitial cells. Am J Pathol. 2002; 161: 2111–2121.CrossrefMedlineGoogle Scholar17 Gustafsson B, Tommeras K, Nordrum I, Loennechen JP, Brunsvik A, Solligard E, Fossmark R, Bakke I, Syverson U, Waldum H. Long-term serotonin administration induces heart valve disease in rats. Circulation. 2005; 111: 1517–1522.LinkGoogle Scholar18 Mekontso-Dessap A, Brouri F, Pascal O, Lechat P, Hanoun N, Lanfumey L, Seif I, Benhaiem-Sigaux N, Kirsch M, Hamon M, Adnot S, Eddahibi S. Deficiency of the 5-hydroxytryptamine transporter gene leads to cardiac fibrosis and valvulopathy in mice. Circulation. 2006; 113: 81–89.LinkGoogle Scholar19 Robiolio P, Rigolin V, Wilson J, Harrison K, Sanders LL, Bashore TM, Feldman JM. Carcinoid heart disease: correlation of high serotonin levels with valvular abnormalities detected by cardiac catheterization and echocardiography. Circulation. 1995; 92: 790–795.CrossrefMedlineGoogle Scholar20 Moller JE, Connolly HM, Rubin J, Seward JB, Modesto K, Pellikka PA. Factors associated with the progression of carcinoid heart disease. N Eng J Med. 2003; 348: 1005–1015.CrossrefMedlineGoogle Scholar21 Mukoyama M, Nakao K, Hosoda K, Suga S, Saito Y, Ogawa Y, Shirakami G, Jougasaki M, Obata K, Yasue H. Brain natriuretic peptide (BNP) as a novel cardiac hormone in humans: evidence for an exquisite dual natriuretic peptide system, ANP and BNP. J Clin Invest. 1991; 87: 1402–1412.CrossrefMedlineGoogle Scholar22 Simula DV, Edwards WD, Tazelaar HD, Connolly HM, Schaff HV. Surgical pathology of carcinoid heart disease: a study of 139 valves from 75 patients spanning 20 years. Mayo Clin Proc. 2002; 77: 139–147.CrossrefMedlineGoogle Scholar23 Ferrans VJ, Roberts WC. The carcinoid endocardial plaque: an ultrastructural study. Hum Pathol. 1976; 7: 387–409.CrossrefMedlineGoogle Scholar24 Ross EM, Roberts WC. The carcinoid syndrome: comparison of 21 necropsy subjects with carcinoid heart disease to 15 necropsy subjects without carcinoid heart disease. Am J Med. 1986; 79: 339–354.Google Scholar25 Howard RJ, Drobac M, Rider WD, Keane TJ, Finlayson J, Silver MD, Wigle ED, Rakowski H. Carcinoid heart disease: diagnosis by two-dimensional echocardiography. Circulation. 1982; 66: 1059–1065.CrossrefMedlineGoogle Scholar26 Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G. Valvular heart disease and the use of dopamine agonists for Parkinson’s disease. N Eng J Med. 2007; 356: 39–46.CrossrefMedlineGoogle Scholar27 Ho SY, Nihoyannopoulos. Anatomy, echocardiography, and normal right ventricular dimensions. Heart. 2006; 92: 2–13.CrossrefMedlineGoogle Scholar28 Mansencal N, Mitry E, Forissier J, Martin F, Redheuil A, Lepere C, Farcot J, Joseph T, Lacombe P, Rougier P, Dubourg O. Assessment of patent foramen ovale in carcinoid heart disease. Am Heart J. 2006; 151: 1129.e1–1129.e6.CrossrefGoogle Scholar29 Connolly HM, Schaff HV, Mullany CJ, Rubin J, Abel MD, Pellikka PA. Surgical management of left sided carcinoid heart disease. Circulation. 2001; 104 (suppl): I-36–I-40.LinkGoogle Scholar30 Fishman AP, Pietra GG. Handling of bioactive materials by the lung. N Engl J Med. 1974; 291: 884–890.CrossrefMedlineGoogle Scholar31 Pandya UH, Pellikka PA, Enriquez-Sarano M, Edwards WD, Schaff HV, Connolly HM. Metastatic carcinoid tumour to the heart: echocardiographic pathologic study of 11 patients. J Am Coll Cardiol. 2002; 40: 1328–1332.CrossrefMedlineGoogle Scholar32 Lundin L, Landelius J, Andren B, Oberg K. Transoesophageal echocardiography improves the diagnostic value of cardiac ultrasound in patients with carcinoid heart disease. Br Heart J. 1990; 64: 190–194.CrossrefMedlineGoogle Scholar33 Bastarrika G, Cao MG, Cano D, Barba J, Saenz de Buruaga JD. Magnetic resonance imaging diagnosis of carcinoid heart disease. J Comput Assist Tomogr. 2005; 29: 756–759.CrossrefMedlineGoogle Scholar34 Mollet NR, Dymarkowski S, Bogaert J. MRI and CT revealing carcinoid heart disease. Eur Radiol. 2003; 13: L14–L18.Google Scholar35 Grant SC, Scarffe JH, Levy RD, Brooks NH. Failure of balloon dilatation of the pulmonary valve in carcinoid pulmonary stenosis. Br Heart J. 1992; 67: 450–453.CrossrefMedlineGoogle Scholar36 Onate A, Alchibar J, Inguanzo R, Peria N, Gochi R. Balloon dilatation of tricuspid and pulmonary valves in carcinoid heart disease. Texas Heart Inst J. 1993; 20: 115–119.MedlineGoogle Scholar37 Hargreaves AD, Pringle SD, Boon NA. Successful balloon dilatation of the pulmonary valve in carcinoid heart disease. Int J Cardiol. 1994; 45: 150–151.CrossrefMedlineGoogle Scholar38 Connolly HM, Nishimura RA, Smith HC, Pellikka PA, Mullany CJ, Kvols LK. Outcome of cardiac surgery for carcinoid heart disease. J Am Coll Cardiol. 1995; 25: 410–416.CrossrefMedlineGoogle Scholar39 Moller JE, Pellikka PA, Bernheim AM, Schaff HV, Rubin J, Connolly HM. Prognosis of carcinoid heart disease: an analysis of 200 cases over two decades. Circulation. 2005; 112: 3320–3327.LinkGoogle Scholar40 Connolly HM, Schaff HV, Mullany CJ, Abel MD, Pellikka PA. Carcinoid heart d" @default.
• W2132173613 created "2016-06-24" @default.
• W2132173613 creator A5026573275 @default.
• W2132173613 creator A5026900612 @default.
• W2132173613 creator A5030484461 @default.
• W2132173613 creator A5070037319 @default.
• W2132173613 date "2007-12-11" @default.
• W2132173613 modified "2023-10-17" @default.
• W2132173613 title "Carcinoid Heart Disease" @default.
• W2132173613 cites W1510892410 @default.
• W2132173613 cites W1565882220 @default.
• W2132173613 cites W1971806094 @default.
• W2132173613 cites W1971861472 @default.
• W2132173613 cites W1979659033 @default.
• W2132173613 cites W1986968622 @default.
• W2132173613 cites W1987154391 @default.
• W2132173613 cites W1988097373 @default.
• W2132173613 cites W1997191999 @default.
• W2132173613 cites W1998364785 @default.
• W2132173613 cites W2000037818 @default.
• W2132173613 cites W2001366774 @default.
• W2132173613 cites W2007342690 @default.
• W2132173613 cites W2034744012 @default.
• W2132173613 cites W2035527717 @default.
• W2132173613 cites W2066173933 @default.
• W2132173613 cites W2066404752 @default.
• W2132173613 cites W2067086939 @default.
• W2132173613 cites W2067541949 @default.
• W2132173613 cites W2073518141 @default.
• W2132173613 cites W2077919897 @default.
• W2132173613 cites W2079846716 @default.
• W2132173613 cites W2085832566 @default.
• W2132173613 cites W2108522840 @default.
• W2132173613 cites W2109324834 @default.
• W2132173613 cites W2113404778 @default.
• W2132173613 cites W2127882317 @default.
• W2132173613 cites W2133106090 @default.
• W2132173613 cites W2133762909 @default.
• W2132173613 cites W2134362869 @default.
• W2132173613 cites W2159785168 @default.
• W2132173613 cites W2162781575 @default.
• W2132173613 cites W2170738046 @default.
• W2132173613 cites W2171421186 @default.
• W2132173613 cites W4231333457 @default.
• W2132173613 cites W4232719912 @default.
• W2132173613 cites W4243944033 @default.
• W2132173613 cites W4244007367 @default.
• W2132173613 doi "https://doi.org/10.1161/circulationaha.107.701367" @default.
• W2132173613 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18071089" @default.
• W2132173613 hasPublicationYear "2007" @default.
• W2132173613 type Work @default.
• W2132173613 sameAs 2132173613 @default.
• W2132173613 citedByCount "181" @default.
• W2132173613 countsByYear W21321736132012 @default.
• W2132173613 countsByYear W21321736132013 @default.
• W2132173613 countsByYear W21321736132014 @default.
• W2132173613 countsByYear W21321736132015 @default.
• W2132173613 countsByYear W21321736132016 @default.
• W2132173613 countsByYear W21321736132017 @default.
• W2132173613 countsByYear W21321736132018 @default.
• W2132173613 countsByYear W21321736132019 @default.
• W2132173613 countsByYear W21321736132020 @default.
• W2132173613 countsByYear W21321736132021 @default.
• W2132173613 countsByYear W21321736132022 @default.
• W2132173613 countsByYear W21321736132023 @default.
• W2132173613 crossrefType "journal-article" @default.
• W2132173613 hasAuthorship W2132173613A5026573275 @default.
• W2132173613 hasAuthorship W2132173613A5026900612 @default.
• W2132173613 hasAuthorship W2132173613A5030484461 @default.
• W2132173613 hasAuthorship W2132173613A5070037319 @default.
• W2132173613 hasBestOaLocation W21321736131 @default.
• W2132173613 hasConcept C126322002 @default.
• W2132173613 hasConcept C164705383 @default.
• W2132173613 hasConcept C177713679 @default.
• W2132173613 hasConcept C2781151469 @default.
• W2132173613 hasConcept C2909397035 @default.
• W2132173613 hasConcept C71924100 @default.
• W2132173613 hasConceptScore W2132173613C126322002 @default.
• W2132173613 hasConceptScore W2132173613C164705383 @default.
• W2132173613 hasConceptScore W2132173613C177713679 @default.
• W2132173613 hasConceptScore W2132173613C2781151469 @default.
• W2132173613 hasConceptScore W2132173613C2909397035 @default.
• W2132173613 hasConceptScore W2132173613C71924100 @default.
• W2132173613 hasIssue "24" @default.
• W2132173613 hasLocation W21321736131 @default.
• W2132173613 hasLocation W21321736132 @default.
• W2132173613 hasOpenAccess W2132173613 @default.
• W2132173613 hasPrimaryLocation W21321736131 @default.
• W2132173613 hasRelatedWork W1875140348 @default.
• W2132173613 hasRelatedWork W1993333140 @default.
• W2132173613 hasRelatedWork W2080860335 @default.
• W2132173613 hasRelatedWork W2619843640 @default.
• W2132173613 hasRelatedWork W2659989079 @default.
• W2132173613 hasRelatedWork W2782219009 @default.
• W2132173613 hasRelatedWork W4242038072 @default.
• W2132173613 hasRelatedWork W4311469719 @default.
• W2132173613 hasRelatedWork W4323033460 @default.
• W2132173613 hasRelatedWork W2288645155 @default.

• next